Design of the Saitama Cardiometabolic Disease and Organ Impairment Study (SCDOIS): A Multidisciplinary Observational Epidemiological Study


Background: In the past few decades, the incidence of cardiometabolic diseases and disorders of the liver, kidney, pancreas, heart, and lung, have been increasing in Western and Asian countries, including Japan. Numerous factors, including abnormal body weight (obesity, overweight, or underweight), infrequent exercise, and other unfavorable lifestyle factors (e.g., smoking and heavy alcohol drinking) have been proposed as risk factors for the development and the progression of diseases, such as type 2 diabetes, hypertension, and dyslipidemia, which ultimately lead to impaired organ function and possibly death. However, the mechanisms that link these risk factors with diseases are still poorly understood, and the potential treatments, including pharmacotherapy and diet, have not been fully evaluated. Methods: In 2011, we established a new collaborative research program, the Saitama Cardiometabolic Disease and Organ Impairment Study (SCDOIS). This multidisciplinary observational epidemiological research study was designed to cover several high-profile diseases and some traditional fields of internal medicine, as well as apparently unrelated fields and particular lifestyle factors, such as unhealthy eating behaviors. In a series of studies, apparently healthy subjects who underwent a regular medical checkup were retrospectively identified based on the results of their medical checkups. In this way, the incidence, prevalence, causality, and clinical relevance of specific conditions and diseases have been investigated in cross-sectional analyses of 100,000 - 200,000 adults, and in longitudinal studies of several thousand subjects who underwent medical checkups multiple times. Discussion: This article describes the background, rationale, purpose, and methods of the SCDOIS. Using data obtained from annual medical checkups, our goals are to 1) establish criteria or identify clinical features that would enable clinicians to detect the presence of abnormal conditions associated with cardiometabolic diseases and/or organ impairment much earlier in the disease course; and 2) determine the potential mechanisms and therapies for these conditions.

Share and Cite:

T. Muneyuki, K. Suwa, H. Oshida, T. Takaoka, A. Kutsuma, T. Yoshida, M. Saito, Y. Hori, Y. Kannno, E. Kanda, M. Kakei, S. Momomura and K. Nakajima, "Design of the Saitama Cardiometabolic Disease and Organ Impairment Study (SCDOIS): A Multidisciplinary Observational Epidemiological Study," Open Journal of Endocrine and Metabolic Diseases, Vol. 3 No. 2, 2013, pp. 144-156. doi: 10.4236/ojemd.2013.32022.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] S. M. Grundy, J. I. Cleeman, S. R. Daniels, K. A. Donato, R. H. Eckel, B. A. Franklin, D. J. Gordon, R. M. Krauss, P. J. Savage, S. C. Smith Jr., J. A. Spertus and F. Costa (American Heart Association, National Heart, Lung, and Blood Institute), “Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement,” Circulation, Vol. 112, 2005, pp. 2735-2752. doi:10.1161/CIRCULATIONAHA.105.169404
[2] P. Kopelman, “Health Risks Associated with Overweight and Obesity,” Obesity Reviews, Vol. 8, Suppl. 1, 2007, pp. 13-17. doi:10.1111/j.1467-789X.2007.00311.x
[3] J. B. Dixon, “The Effect of Obesity on Health Outcomes,” Molecular and Cellular Endocrinology, Vol. 316, No. 2, 2010, pp. 104-108. doi:10.1016/j.mce.2009.07.008
[4] D. W. Lam and D. LeRoith, “The Worldwide Diabetes Epidemic,” Current Opinion in Endocrinology, Diabetes and Obesity, Vol. 19, No. 2, 2012, pp. 93-96.
[5] V. Sharma and V. Kumar, “Diabetes in Asia,” Lancet, Vol. 375, No. 9719, 2010, p. 982. doi:10.1016/S0140-6736(10)60435-7
[6] K. Iseki, Y. Ikemiya, C. Iseki, et al., “Proteinuria and the Risk of Developing End-Stage Renal Disease,” Kidney International, Vol. 63, 2003, pp. 1468-1474. doi:10.1046/j.1523-1755.2003.00868.x
[7] M. Tozawa, K. Iseki, C. Iseki, et al., “Influence of Smoking and Obesity on the Development of Proteinuria,” Kidney International, Vol. 62, 2002, pp. 956-962. doi:10.1046/j.1523-1755.2002.00506.x
[8] S. Tsugane, “Alcohol, Smoking, and Obesity Epidemiology in Japan,” Journal of Gastroenterology and Hepatology, Vol. 27, Suppl. 2, 2012, pp. 121-126. doi:10.1111/j.1440-1746.2011.07021.x
[9] B. A. Neuschwander-Tetri and S. H. Caldwell, “Nonalcoholic Steatohepatitis: Summary of an AASLD Single Topic Conference,” Hepatology, Vol. 37, No. 5, 2003, pp. 1202-1219. doi:10.1053/jhep.2003.50193
[10] B. W. Smith and L. A. Adams, “Non-Alcoholic Fatty Liver Disease,” Critical Reviews in Clinical Laboratory Sciences, Vol. 48, 2011, pp. 97-113. doi:10.3109/10408363.2011.596521
[11] S. H. Jee, J. W. Sull, J. Park, et al., “Body-Mass Index and Mortality in Korean Men and Women,” New England Journal of Medicine, Vol. 355, 2006, pp. 779-787. doi:10.1056/NEJMoa054017
[12] A. Berrington de Gonzalez, P. Hartge, J. R. Cerhan, et al., “Body-Mass Index and Mortality among 1.46 Million White Adults,” New England Journal of Medicine, Vol. 363, 2010, pp. 2211-2219. doi:10.1056/NEJMoa1000367
[13] W. Zheng, D. F. McLerran, B. Rolland, et al., “Association between Body-Mass Index and Risk of Death in More than 1 Million Asians,” New England Journal of Medicine, Vol. 364, 2011, pp. 719-729. doi:10.1056/NEJMoa1010679
[14] S. Saitoh, “The Tanno-Soubetsu Study,” Nihon Rinsho, Vol. 69, Suppl. 1, 2011, pp. 58-62.
[15] Y. Kokubo, “The Association of Cardiovascular Disease with Metabolic Syndrome and Its Risk Factors in Japanese Urban Cohort: The Suita Study,” Nihon Rinsho, Vol. 69, Suppl. 1, 2011, pp. 68-76.
[16] Y. Kiyohara, “The Hisayama Study,” Nihon Rinsho, Vol. 69, Suppl. 1, 2011, pp. 63-67.
[17] H. Sone, “Diabetes Mellitus and Metabolic Syndrome in Epidemiological Studies,” Nihon Rinsho, Vol. 69, Suppl. 1, 2011, pp. 93-100.
[18] “Saitama Prefecture at a Glance,” 2012.
[19] “Saitama Health Promotion,” 2013.
[20] Y. Li, H. Yatsuya, H. Iso, K. Tamakoshi and H. Toyoshima, “Incidence of Metabolic Syndrome According to Combinations of Lifestyle Factors among Middle-Aged Japanese Male Workers,” Preventive Medicine, Vol. 51, No. 2, 2010, pp. 118-122. doi:10.1016/j.ypmed.2010.04.016
[21] A. Morimoto, Y. Ohno, Y. Tatsumi, Y. Nishigaki, F. Maejima, S. Mizuno and S. Watanabe, “Risk of Smoking and Body Mass Index for Incidence of Diabetes Mellitus in a Rural Japanese Population,” Preventive Medicine, Vol. 54, No. 5, 2012, pp. 341-344. doi:10.1016/j.ypmed.2012.02.016
[22] Ministry of Health, “Labour, and Welfare: Health Examination and Guidance Program for Japanese Adults,” 2008.
[23] E. Chen and G. E. Miller, “Socioeconomic Status and Health: Mediating and Moderating Factors,” Annual Review of Clinical Psychology, Vol. 9, 2013, pp. 723-749.
[24] R. E. Patzer and W. M. McClellan, “Influence of Race, Ethnicity and Socioeconomic Status on Kidney Disease,” Nature Reviews Nephrology, Vol. 8, 2012, pp. 533-541. doi:10.1038/nrneph.2012.117
[25] N. M. Hawkins, P. S. Jhund, J. J. McMurray and S. Capewell, “Heart Failure and Socioeconomic Status: Accumulating Evidence of Inequality,” European Journal of Heart Failure, Vol. 14, No. 2, 2012, pp. 138-146. doi:10.1093/eurjhf/hfr168
[26] R. Otsuka, K. Tamakoshi, H. Yatsuya, et al., “Eating Fast Leads to Obesity: Findings Based on Self-Administered Questionnaires among Middle-Aged Japanese Men and Women,” Journal of Epidemiology, Vol. 16, No. 3, 2006, pp. 117-124. doi:10.2188/jea.16.117
[27] K. Maruyama, S. Sato, T. Ohira, et al., “The Joint Impact on Being Overweight of Self Reported Behaviours of Eating Quickly and Eating until Full: Cross Sectional Survey,” BMJ, Vol. 337, 2008, p. a2002.
[28] S. Tanihara, T. Imatoh, M. Miyazaki, et al., “Retrospective Longitudinal Study on the Relationship between 8-Year Weight Change and Current Eating Speed,” Appetite, Vol. 57, No. 1, 2011, pp. 179-183. doi:10.1016/j.appet.2011.04.017
[29] M. Sakurai, K. Nakamura, K. Miura, et al., “Self-Reported Speed of Eating and 7-Year Risk of Type 2 Diabetes Mellitus in Middle-Aged Japanese Men,” Metabolism, Vol. 61, No. 11, 2012, pp. 1566-1571. doi:10.1016/j.metabol.2012.04.005
[30] T. Ohkuma, H. Fujii, M. Iwase, et al., “Impact of Eating Rate on Obesity and Cardiovascular Risk Factors According to Glucose Tolerance Status: The Fukuoka Diabetes Registry and the Hisayama Study,” Diabetologia, Vol. 56, No. 1, 2013, pp. 70-77.
[31] WHO Expert Consultation, “Appropriate Body-Mass Index for Asian Populations and Its Implications for Policy and Intervention Strategies,” Lancet, Vol. 363, No. 9403, 2004, pp. 157-163. doi:10.1016/S0140-6736(03)15268-3
[32] K. Nakajima, H. Yamaoka, K. Morita, M. Ebata, S. Eguchi, T. Muneyuki and H. Munakata, “Elderly People with Low Body Weight May Have Subtle Low-Grade Inflammation,” Obesity (Silver Spring), Vol. 17, No. 4, 2009, pp. 803-808. doi:10.1038/oby.2008.596
[33] M. Nagai, S. Kuriyama, M. Kakizaki, K. Ohmori-Matsuda, T. Sone, A. Hozawa, M. Kawado, S. Hashimoto and I. Tsuji, “Impact of Obesity, Overweight and Underweight on Life Expectancy and Lifetime Medical Expenditures: The Ohsaki Cohort Study,” BMJ Open, Vol. 2, No. 3, 2012, Article ID: e000940. doi:10.1136/bmjopen-2012-000940
[34] D. J. Nieves, M. Cnop, B. Retzlaff, C. E. Walden, J. D. Brunzell, R. H. Knopp and S. E. Kahn, “The Atherogenic Lipoprotein Profile Associated with Obesity and Insulin Resistance Is Largely Attributable to Intra-Abdominal Fat,” Diabetes, Vol. 52, No. 1, 2003, pp. 172-179. doi:10.2337/diabetes.52.1.172
[35] S. Zhu, S. B. Heymsfield, H. Toyoshima, Z. Wang, A. Pietrobelli and S. Heshka, “Race-Ethnicity-Specific Waist Circumference Cutoffs for Identifying Cardiovascular Disease Risk Factors,” American Journal of Clinical Nutrition, Vol. 81, No. 2, 2005, pp. 409-415.
[36] R. Ness-Abramof and C. M. Apovian, “Waist Circumference Measurement in Clinical Practice,” Nutrition in Clinical Practice, Vol. 23, No. 4, 2008, 397-404. doi:10.1177/0884533608321700
[37] T. Miyawaki, N. Azuma, Y. Fukunaga and N. Kobayashi, “Abdomen Specific Bioelectrical Impedance Analysis (BIA) Methods for Evaluation of Visceral Fat Accumulation,” Nihon Rinsho, Vol. 69, No. S1, 2011, pp. S470-S472.
[38] S. J. Loveday, J. M. Thompson and E. A. Mitchell, “Bioelectrical Impedance for Measuring Percentage Body Fat in Young Persons with Down Syndrome: Validation with Dual-Energy Absorptiometry,” Acta Paediatrica, Vol. 101, No. 11, 2012, e491-e495. doi:10.1111/j.1651-2227.2012.02821.x
[39] K. H. Pietilainen, S. Kaye, A. Karmi, L. Suojanen, A. Rissanen and K. A. Virtanen, “Agreement of Bioelectrical Impedance with Dual-Energy X-Ray Absorptiometry and MRI to Estimate Changes in Body Fat, Skeletal Muscle and Visceral Fat during a 12-Month Weight Loss Intervention,” The British Journal of Nutrition, Vol. 109, No. 10, 2012, pp. 1-7.
[40] Y. Balarajan and E. Villamor, “Nationally Representative Surveys Show Recent Increases in the Prevalence of Overweight and Obesity among Women of Reproductive Age in Bangladesh, Nepal, and India,” The Journal of Nutrition, Vol. 139, No. 11, 2009, pp. 2139-2144. doi:10.3945/jn.109.112029
[41] S. E. Gariballa, “Nutritional Factors in Stroke,” The British Journal of Nutrition, Vol. 84, No. 1, 2000, pp. 5-17. doi:10.1017/S0007114500001173
[42] H. Shibata, “Nutritional Factors on Longevity and Quality of Life in Japan,” The Journal of Nutrition, Health & Aging, Vol. 5, No. 2, 2001, pp. 97-102.
[43] A. González Madrono, A. Mancha, F. J. Rodríguez, J. I. de Ulibarri and J. Culebras, “The Use of Biochemical and Immunological Parameters in Nutritional Screening and Assessment,” Nutricion Hospitalaria, Vol. 26, No. 3, 2011, pp. 594-601.
[44] D. Bunout, G. Barrera, M. P. de la Maza, L. Leiva, V. Gattas and S. Hirsch, “Height Reduction, Determined Using Knee Height Measurement as a Risk Factor or Predictive Sign for Osteoporosis in Elderly Women,” Nutrition, Vol. 23, No. 11, 2007, 794-797. doi:10.1016/j.nut.2007.08.012
[45] A. Kjensli, M. Ryg, J. A. Falch, G. Armbrecht, L. M. Diep, E. F. Eriksen and I. Ellingsen, “Does Body Height Reduction Influence Interpretation of Lung Function in COPD Patients?” European Respiratory Journal, Vol. 36, No. 3, 2010, pp. 540-548. doi:10.1183/09031936.00148609
[46] American Diabetes Association, “Diagnosis and Classification of Diabetes Mellitus,” Diabetes Care, Vol. 33, No. S1, pp. S62-S69. doi:10.2337/dc10-S062
[47] N. Unwin, J. Shaw, P. Zimmet, et al., “Impaired Glucose Tolerance and Impaired Fasting Glycaemia: The Current Status on Definition and Intervention,” Diabetic Medicine, Vol. 19, No. 9, 2002, pp. 708-723. doi:10.1046/j.1464-5491.2002.00835.x
[48] Committee for the Diagnostic Criteria of Metabolic Syndrome, “The Definition and Diagnostic Criteria of Metabolic Syndrome,” Nippon Naika Gakkai Zasshi, Vol. 94, No. 4, 2005, pp. 794-809. doi:10.2169/naika.94.794
[49] A. Kashiwagi, M. Kasuga, E. Araki, et al., “International Clinical Harmonization of Glycated Hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program Values,” Journal of Diabetes Investigation, Vol. 3, No. 1, 2012, pp. 39-40. doi:10.1111/j.2040-1124.2012.00207.x
[50] W. T. Friedewald, R. I. Levy and D. S. Fredrickson, “Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, without Use of the Preparative Ultracentrifuge,” Clinical Chemistry, Vol. 18, No. 6, 1972, pp. 499-502.
[51] A. Sniderman, M. McQueen, J. Contois, K. Williams and C. D. Furberg, “Why Is Non-High-Density Lipoprotein Cholesterol a Better Marker of the Risk of Vascular Disease than Low-Density Lipoprotein Cholesterol?” Journal of Clinical Lipidology, Vol. 4, No. 3, 2010, pp. 152-155. doi:10.1016/j.jacl.2010.03.005
[52] V. Ramjee, L. S. Sperling and T. A. Jacobson, “Non-High-Density Lipoprotein Cholesterol versus Apolipo-protein B in Cardiovascular Risk Stratification: Do the Math,” Journal of the American College of Cardiology, Vol. 58, No. 5, 2011, pp. 457-463. doi:10.1016/j.jacc.2011.05.009
[53] J. S. Rana and S. M. Boekholdt, “Should We Change Our Lipid Management Strategies to Focus on Non-High-Density Lipoprotein Cholesterol?” Current Opinion in Cardiology, Vol. 25, No. 6, 2010, pp. 622-626. doi:10.1097/HCO.0b013e32833f0365
[54] K. Miki and Y. Urita, “Using Serum Pepsinogens Wisely in a Clinical Practice,” Journal of Digestive Diseases, Vol. 8, No. 1, 2007, pp. 8-14. doi:10.1111/j.1443-9573.2007.00278.x
[55] C. Mukoubayashi, K. Yanaoka, H. Ohata, K. Arii, H. Tamai, M. Oka and M. Ichinose, “Serum Pepsinogen and Gastric Cancer Screening,” Internal Medicine, Vol. 46, No. 6, 2007, pp. 261-266. doi:10.2169/internalmedicine.46.6181
[56] M. N. Weck and H. Brenner, “Association of Helicobacter pylori Infection with Chronic Atrophic Gastritis: Meta-Analyses according to Type of Disease Definition,” International Journal of Cancer, Vol. 123, No. 4, 2008, pp. 874-881. doi:10.1002/ijc.23539
[57] J. Kawashima, S. Ohno, T. Sakurada, H. Takabayashi, M. Kudo, S. Ro, S. Kato and K. Yakabi, “Circulating Acylated Ghrelin Level Decreases in accordance with the Extent of Atrophic Gastritis,” Journal of Gastroenterology, Vol. 44, No. 10, 2009, pp. 1046-1054. doi:10.1007/s00535-009-0120-0
[58] H. Osawa, “Ghrelin and Helicobacter pylori Infection,” World Journal of Gastroenterology, Vol. 14, No. 41, 2008, pp. 6327-6333. doi:10.3748/wjg.14.6327
[59] N. E. Hill, K. G. Murphy and M. Singer, “Ghrelin, Appetite and Critical Illness,” Current Opinion in Critical Care, Vol. 18, No. 2, 2012, pp. 199-205. doi:10.1097/MCC.0b013e3283514b01
[60] H. Kirchner, K. M. Heppner and M. H. Tschop, “The Role of Ghrelin in the Control of Energy Balance,” Handbook of Experimental Pharmacology, Vol. 209, 2012, pp. 161-184. doi:10.1007/978-3-642-24716-3_7
[61] T. Senmaru, M. Fukui, M. Kuroda, M. Tanaka, E. Ushigome, K. Sakabe, N. Nakanishi, Y. Mineoka, M. Asano, M. Yamazaki, G. Hasegawa and N. Nakamura, “Serum Pepsinogen I/II Ratio Is Correlated with Albuminuria in Patients with Type 2 Diabetes,” Endocrine Journal, Vol. 60, No. 2, 2012, pp. 161-166.
[62] R. K. Schindhelm, M. Diamant, J. M. Dekker, M. E. Tushuizen, T. Teerlink and R. J. Heine, “Alanine Aminotransferase as a Marker of Non-Alcoholic Fatty Liver Disease in Relation to Type 2 Diabetes Mellitus and Cardiovascular Disease,” Diabetes/Metabolism Research and Reviews, Vol. 22, No. 6, 2006, pp. 437-443. doi:10.1002/dmrr.666
[63] Y. Chang, S. Ryu, E. Sung and Y. Jang, “Higher Concentrations of Alanine Aminotransferase within the Reference Interval Predict Nonalcoholic Fatty Liver Disease,” Clinical Chemistry, Vol. 53, No. 4, 2007, pp. 686-692. doi:10.1373/clinchem.2006.081257
[64] N. Ghouri, D. Preiss and N. Sattar, “Liver Enzymes, Nonalcoholic Fatty Liver Disease, and Incident Cardiovascular Disease: A Narrative Review and Clinical Perspective of Prospective Data,” Hepatology, Vol. 52, No. 3, 2010, pp. 1156-1161. doi:10.1002/hep.23789
[65] L. A. Adams, O. R. Waters, M. W. Knuiman, R. R. Elliott and J. K. Olynyk, “NAFLD as a Risk Factor for the Development of Diabetes and the Metabolic Syndrome: An Eleven-Year Follow-Up Study,” The American Journal of Gastroenterology, Vol. 104, No. 4, 2009, pp. 861-867.
[66] A. Iacobellis, M. Marcellini, A. Andriulli, et al., “Non Invasive Evaluation of Liver Fibrosis in Paediatric Patients with Nonalcoholic Steatohepatitis,” World Journal of Gastroenterology, Vol. 12, No. 48, 2006, pp. 7821-7825.
[67] A. Vallet-Pichard, V. Mallet, B. Nalpas, et al., FIB-4: An Inexpensive and Accurate Marker of Fibrosis in HCV Infection,” Hepatology, Vol. 46, No. 1, 2007, pp. 32-36. doi:10.1002/hep.21669
[68] C. T. Wai, J. K. Greenson, R. J. Fontana, et al., “A Simple Noninvasive Index Can Predict both Significant Fibrosis and Cirrhosis in Patients with Chronic Hepatitis C,” Hepatology, Vol. 38, No. 2, 2003, pp. 518-526. doi:10.1053/jhep.2003.50346
[69] B. Yegneswaran, C. S. Pitchumoni, B. Yegneswaran, et al., “When Should Serum Amylase and Lipase Levels Be Repeated in a Patient with Acute Pancreatitis?” Cleveland Clinic Journal of Medicine, Vol. 77, No. 4, 2010, pp. 230-231. doi:10.3949/ccjm.77a.09083
[70] J. Skrha and J. Stěpán, “Clinical Significance of Amylase Isoenzyme Determination,” Acta Universitatis Carolinae. Medica. Monographia, Vol. 120, 1987, pp. 1-81.
[71] C. Pieper-Bigelow, A. Strocchi and M. D. Levitt, “Where Does Serum Amylase Come from and Where Does It Go?” Gastroenterology Clinics of North America, Vol. 19, No. 4, 1990, pp. 793-810.
[72] M. J. Collen, A. F. Ansher, A. B. Chapman, et al., “Serum Amylase in Patients with Renal Insufficiency and Renal Failure,” The American Journal of Gastroenterology, Vol. 85, No. 10, 1990, pp. 1377-1380.
[73] J. E. Domínguez-Munoz, O. Pieramico, M. Büchler, et al., “Ratios of Different Serum Pancreatic Enzymes in the Diagnosis and Staging of Chronic Pancreatitis,” Digestion, Vol. 54, No. 4, 1993, pp. 231-236. doi:10.1159/000201042
[74] R. O. Wolf, V. S. Hubbard, B. K. Gillard, et al., “Three Methods Compared for Determination of Pancreatic and Salivary Amylase Activity in Serum of Cystic Fibrosis Patients,” Clinical Chemistry, Vol. 32, No. 2, 1986, pp. 296-300.
[75] K. Nakajima, T. Nemoto, T. Muneyuki, et al., “Low Serum Amylase in Association with Metabolic Syndrome and Diabetes: A Community-Based Study,” Cardio Vascular Diabetology, Vol. 10, No. 34, 2011. doi:10.1186/1475-2840-10-34
[76] K. Nakajima, H. Oshida, T. Muneyuki, M. Saito, Y. Hori, H. Fuchigami, M. Kakei and H. Munakata, “Independent Association between Low Serum Amylase and Non-Alcoholic Fatty Liver Disease in Asymptomatic Adults: A Cross-Sectional Observational Study,” BMJ Open, Vol. 3, No. 1, 2013, Article ID: e002235. doi:10.1136/bmjopen-2012-002235
[77] A. S. Levey, J. Coresh, E. Balk, et al., “National Kidney Foundation: National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification,” Annals of Internal Medicine, Vol. 139, No. 2, 2003, pp. 137-147. doi:10.7326/0003-4819-139-2-200307150-00013
[78] R. M. Tanner, T. M. Brown and P. Muntner, “Epidemiology of Obesity, the Metabolic Syndrome, and Chronic Kidney Disease,” Current Hypertension Reports, Vol. 14, No. 2, 2012, pp. 152-159. doi:10.1007/s11906-012-0254-y
[79] M. Praga and E. Morales, “Obesity, Proteinuria and Progression of Renal Failure,” Current Opinion in Nephrology and Hypertension, Vol. 15, No. 5, 2006, pp. 481-486.
[80] S. Matsuo, E. Imai, M. Horio, et al., “Revised Equations for Estimated GFR from Serum Creatinine in Japan,” American Journal of Kidney Diseases, Vol. 53, No. 6, 2009, pp. 982-992.doi:10.1053/j.ajkd.2008.12.034
[81] J. A. Vassalotti, L. A. Stevens and A. S. Levey, “Testing for Chronic Kidney Disease: A Position Statement from the National Kidney Foundation,” American Journal of Kidney Diseases, Vol. 50, 2007, pp. 169-180. doi:10.1053/j.ajkd.2007.06.013
[82] A. S. Levey, K. U. Eckardt, Y. Tsukamoto, A. Levin, J. Coresh, J. Rossert, D. De Zeeuw, T. H. Hostetter, N. Lameire and G. Eknoyan, “Definition and Classification of Chronic Kidney Disease: A Position Statement from Kidney Disease: Improving Global Outcomes (KDIGO),” Kidney International, Vol. 67, 2005, pp. 2089-2100. doi:10.1111/j.1523-1755.2005.00365.x
[83] P. Libby, P. M. Ridker and A. Maseri, “Inflammation and Atherosclerosis,” Circulation, Vol. 105, 2002, pp. 1135-1143. doi:10.1161/hc0902.104353
[84] M. J. Gunter, R. Stolzenberg-Solomon, A. J. Cross, et al., “A Prospective Study of Serum C-Reactive Protein and Colorectal Cancer Risk in Men,” Cancer Research, Vol. 66, 2006, pp. 2483-2487. doi:10.1158/0008-5472.CAN-05-3631
[85] V. Chiurchiù and M. Maccarrone, “Chronic Inflammatory Disorders and Their Redox Control: From Molecular Mechanisms to Therapeutic Opportunities,” Antioxidants & Redox Signaling, Vol. 15, No. 9, 2011, pp. 2605-2641. doi:10.1089/ars.2010.3547
[86] E. T. Yeh, “High-Sensitivity C-Reactive Protein as a Risk Assessment Tool for Cardiovascular Disease,” Clinical Cardiology, Vol. 28, No. 9, 2005, pp. 408-412. doi:10.1002/clc.4960280905
[87] K. Musunuru, B. G. Kral, R. S. Blumenthal, V. Fuster, C. Y. Campbell, T. J. Gluckman, R. A. Lange, E. J. Topol, J. T. Willerson, M. Y. Desai, M. H. Davidson and S. Mora, “The Use of High-Sensitivity Assays for C-Reactive Protein in Clinical Practice,” Nature Clinical Practice Cardiovascular Medicine, Vol. 5, No. 10, 2008, pp. 621-635. doi:10.1038/ncpcardio1322
[88] S. Devaraj, S. Valleggi, D. Siegel and I. Jialal, “Role of C-Reactive Protein in Contributing to Increased Cardiovascular Risk in Metabolic Syndrome,” Current Atherosclerosis Reports, Vol. 12, No. 2, 2010, pp. 110-118. doi:10.1007/s11883-010-0098-3
[89] E. Cavusoglu, V. Chopra, A. Gupta, C. Ruwende, S. Yanamadala, C. Eng, L. T. Clark, D. J. Pinsky and J. D. Marmur, “Usefulness of the White Blood Cell Count as a Predictor of Angiographic Findings in an Unselected Population Referred for Coronary Angiography,” American Journal of Cardiology, Vol. 98, No. 9, 2006, pp. 1189-1193. doi:10.1016/j.amjcard.2006.05.048
[90] Y. J. Lee, Y. H. Shin, J. K. Kim, J. Y. Shim, D. R. Kang and H. R. Lee, “Metabolic Syndrome and Its Association with White Blood Cell Count in Children and Adolescents in Korea: The 2005 Korean National Health and Nutrition Examination Survey,” Nutrition, Metabolism & Cardiovascular Diseases, Vol. 20, No. 3, 2010, pp. 165-172. doi:10.1016/j.numecd.2009.03.017
[91] S. B. Chen, Y. C. Lee, K. H. Ser, J. C. Chen, S. C. Chen, H. F. Hsieh and W. J. Lee, “Serum C-Reactive Protein and White Blood Cell Count in Morbidly Obese Surgical Patients,” Obesity Surgery, Vol. 19, No. 4, 2009, pp. 461-466.doi:10.1007/s11695-008-9619-3
[92] A. K. Agarwal and S. D. Katz, “Future Directions in Management of Anemia in Heart Failure,” Heart Failure Clinics, Vol. 6, No. 3, 2010, pp. 385-395. doi:10.1016/j.hfc.2010.03.004
[93] S. von Haehling, M. S. Anker, E. A. Jankowska, P. Ponikowski and S. D. Anker, “Anemia in Chronic Heart Failure: Can We Treat? What to Treat?” Heart Failure Reviews, Vol. 17, No. 2, 2012, pp. 203-210. doi:10.1007/s10741-011-9283-x
[94] A. K. Singh, “Diabetes, Anemia and CKD: Why TREAT? Current Diabetes Reports, Vol. 10, No. 4, 2010, pp. 291-296. doi:10.1007/s11892-010-0123-5
[95] S. Fishbane and N. Miyawaki, “Anemia Treatment in Chronic Kidney Disease Accompanied by Diabetes Mellitus or Congestive Heart Failure,” Kidney International, Vol. 77, No. 3, 2010, pp. 175-177.
[96] E. Villar, M. Lievre, M. Kessler, V. Lemaitre, E. Alamartine, M. Rodier, M. Francois, P. Zaoui, O. Moranne, G. Choukroun, A. Guerraoui, A. Jolivot, G. Janin, B. Branger, A. E. Heng, C. Boudray, A. Bissery, M. Rabilloud and C. Pouteil-Noble, “Anemia Normalization in Patients with Type 2 Diabetes and Chronic Kidney Disease: Results of the NEPHRODIAB2 Randomized Trial,” Journal of Diabetes and Its Complications, Vol. 25, No. 4, 2011, pp. 237-243. doi:10.1016/j.jdiacomp.2011.03.003
[97] A. Howarth and G. R. Shone, “Ageing and the Auditory System,” Postgraduate Medical Journal, Vol. 82, 2006, pp. 166-171.doi:10.1136/pgmj.2005.039388
[98] X. Z. Liu and D. Yan, “Ageing and Hearing Loss,” The Journal of Pathology, Vol. 211, No. 2, 2007, pp. 188-197.
[99] Q. Huang and J. Tang, “Age-Related Hearing Loss or Presbycusis,” European Archives of Oto-Rhino-Laryngology, Vol. 267, No. 8, 2010, pp. 1179-1191. doi:10.1007/s00405-010-1270-7
[100] L. D. Lowry and S. R. Isaacson, “Study of 100 Patients with Bilateral Sensorineural Hearing Loss for Lipid Abnormalities,” Annals of Otology, Rhinology, Laryngology, Vol. 87, No. 3, 1978, pp. 404-408.
[101] I. Pyykko, K. Koskimies, J. Starck, J. Pekkarinen, R. Inaba, “Evaluation of Factors Affecting Sensory Neural Hearing Loss,” Acta Oto-laryngologica, Vol. 105, No. S449, 1988, pp. 155-158. doi:10.3109/00016488809106400
[102] K. Suzuki, M. Kaneko and K. Murai, “Influence of Serum Lipids on Auditory Function,” Laryngoscope, Vol. 110, No. 10, 2000, pp. 1736-1738. doi:10.1097/00005537-200010000-00033
[103] V. Kakarlapudi, R. Sawyer and H. Staecker, “The Effect of Diabetes on Sensorineural Hearing Loss,” Otology & Neurotology, Vol. 24, No. 3, 2003, 382-386. doi:10.1097/00129492-200305000-00006
[104] D. F. Austin, D. Konrad-Martin, S. Griest, G. P. Mc-Millan, D. McDermott and S. Fausti, “Diabetes-Related Changes in Hearing,” Laryngoscope, Vol. 119, No. 9, 2009, pp. 1788-1796. doi:10.1002/lary.20570
[105] K. E. Bainbridge, Y. J. Cheng and C. C. Cowie, “Potential Mediators of Diabetes-Related Hearing Impairment in the U.S. Population: National Health and Nutrition Examination Survey 1999-2004,” Diabetes Care, Vol. 33, No. 4, 2010, pp. 811-816. doi:10.2337/dc09-1193
[106] M. E. Cupples, P. M. Hart, A. Johnston and A. J. Jackson, “Improving Healthcare Access for People with Visual Impairment and Blindness,” BMJ, Vol. 344, 2012, Article ID: e542. doi:10.1136/bmj.e542
[107] J. M. Furtado, V. C. Lansingh, M. J. Carter, M. F. Milanese, B. N. Pena, H. A. Ghersi, P. L. Bote, M. E. Nano and J. C. Silva, “Causes of Blindness and Visual Impairment in Latin America,” Survey of Ophthalmology, Vol. 57, No. 2 , 2012, pp. 149-177. doi:10.1016/j.survophthal.2011.07.002
[108] D. Pascolini and S. P. Mariotti, “Global Estimates of Visual Impairment: 2010,” British Journal of Ophthalmology, Vol. 96, No. 5, 2012, pp. 614-618. doi:10.1136/bjophthalmol-2011-300539
[109] F. Ko, S. Vitale, C. F. Chou, M. F. Cotch, J. Saaddine and D. S. Friedman, “Prevalence of Nonrefractive Visual Impairment in U.S. Adults and Associated Risk Factors, 1999-2002 and 2005-2008,” The Journal of the American Medical Association, Vol. 308, No. 22, 2012, pp. 2361-2368.
[110] C. Zocchetti, D. Consonni and P. A. Bertazzi, “Relationship between Prevalence Rate Ratios and Odds Ratios in Cross-Sectional Studies,” International Journal of Epidemiology, Vol. 26, No. 1, 1997, pp. 220-223. doi:10.1093/ije/26.1.220

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.